Literature DB >> 3579256

Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers.

D P Healy, R E Polk, M L Garson, D T Rock, T J Comstock.   

Abstract

A pharmacokinetic comparison of the two recommended dosages of vancomycin given as multiple doses has not been previously performed. Eleven adult subjects with normal renal function randomly received 500 mg every 6 h (five doses) and, later, 1,000 mg every 12 h (three doses). Each dose was infused over 1 h, and regimens were separated by 1 week. Compared with the two-compartment fit, a three-compartment fit significantly reduced the residual weighted sums of squares. Accumulation occurred for both regimens after repeated dosing and was independent of dose. At steady state, concentrations in serum at 1 h showed little variation for the 1,000- or the 500-mg dose regimen (33.7 +/- 3.8 versus 22.6 +/- 3.2 micrograms/ml); trough concentrations were 7.9 +/- 1.7 versus 11.2 +/- 2.2 micrograms/ml, respectively. With the 1,000-mg dose, the terminal half-life was 7.7 +/- 1.8 h, steady-state area under the curve for the dose interval was 227 +/- 28.3 micrograms X h/ml, and total body clearance was 86.1 +/- 8.9 ml/min per 1.73 m2. The red-man syndrome occurred in 9 of 11 volunteers who received 1,000-mg doses and in none of those who received 500-mg doses. We concluded that vancomycin disposition in healthy adults with normal renal function is best described by a three-compartment model, there is relatively little variation in vancomycin disposition in normal volunteers, significant accumulation occurs with multiple dosing, it is inappropriate to use the same therapeutic window for both regimens, and the pharmacokinetics of vancomycin justify a 12-h dose interval; however, a 1-g dose is associated with a significantly greater incidence of the red-man syndrome.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3579256      PMCID: PMC174739          DOI: 10.1128/AAC.31.3.393

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Laboratory evaluation of five assay methods for vancomycin: bioassay, high-pressure liquid chromatography, fluorescence polarization immunoassay, radioimmunoassay, and fluorescence immunoassay.

Authors:  M A Pfaller; D J Krogstad; G G Granich; P R Murray
Journal:  J Clin Microbiol       Date:  1984-09       Impact factor: 5.948

2.  Monitoring vancomycin therapy.

Authors:  M J Rybak; S C Boike
Journal:  Drug Intell Clin Pharm       Date:  1986-10

Review 3.  Vancomycin: an update.

Authors:  R P Cheung; J T DiPiro
Journal:  Pharmacotherapy       Date:  1986 Jul-Aug       Impact factor: 4.705

4.  Adverse effects of vancomycin administered in the perioperative period.

Authors:  P A Southorn; D J Plevak; A J Wright; W R Wilson
Journal:  Mayo Clin Proc       Date:  1986-09       Impact factor: 7.616

5.  Vancomycin.

Authors:  J E Geraci; P E Hermans
Journal:  Mayo Clin Proc       Date:  1983-02       Impact factor: 7.616

6.  Vancomycin pharmacokinetics in normal and morbidly obese subjects.

Authors:  R A Blouin; L A Bauer; D D Miller; K E Record; W O Griffen
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

7.  Vancomycin pharmacokinetics in critically ill patients.

Authors:  J J Garaud; B Regnier; F Inglebert; F Faurisson; J Bauchet; F Vachon
Journal:  J Antimicrob Chemother       Date:  1984-12       Impact factor: 5.790

8.  Vancomycin therapy in patients with impaired renal function: a nomogram for dosage.

Authors:  R C Moellering; D J Krogstad; D J Greenblatt
Journal:  Ann Intern Med       Date:  1981-03       Impact factor: 25.391

9.  Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981.

Authors:  B F Farber; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

Review 10.  Serum level monitoring of antibacterial drugs. A review.

Authors:  M Wenk; S Vozeh; F Follath
Journal:  Clin Pharmacokinet       Date:  1984 Nov-Dec       Impact factor: 6.447

View more
  45 in total

Review 1.  Rate and extent of drug accumulation after multiple dosing revisited.

Authors:  Dion R Brocks; Reza Mehvar
Journal:  Clin Pharmacokinet       Date:  2010-07       Impact factor: 6.447

2.  In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus.

Authors:  Mao Hagihara; Dora E Wiskirchen; Joseph L Kuti; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2011-10-17       Impact factor: 5.191

3.  Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects.

Authors:  J P Shaw; J Seroogy; K Kaniga; D L Higgins; M Kitt; S Barriere
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

Review 4.  Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy.

Authors:  Federico Pea; Pierluigi Viale; Federica Pavan; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

5.  Daptomycin and tigecycline have broader effective dose ranges than vancomycin as prophylaxis against a Staphylococcus aureus surgical implant infection in mice.

Authors:  Jared A Niska; Jonathan H Shahbazian; Romela Irene Ramos; Jonathan R Pribaz; Fabrizio Billi; Kevin P Francis; Lloyd S Miller
Journal:  Antimicrob Agents Chemother       Date:  2012-02-27       Impact factor: 5.191

6.  Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus.

Authors:  Noe Reyes; Robert Skinner; Koné Kaniga; Kevin M Krause; Josephine Shelton; Glenmar P Obedencio; Alexander Gough; Michael Conner; Sharath S Hegde
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

7.  Are higher vancomycin doses needed in ventricle-external shunted patients?

Authors:  Meritxell Pujal; Dolors Soy; Carles Codina; Josep Ribas
Journal:  Pharm World Sci       Date:  2006-10-26

Review 8.  Pharmacokinetic optimisation of vancomycin therapy.

Authors:  W G Leader; M H Chandler; M Castiglia
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

9.  Vancomycin pharmacokinetics in burn patients and intravenous drug abusers.

Authors:  M J Rybak; L M Albrecht; J R Berman; L H Warbasse; C K Svensson
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

Review 10.  Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions.

Authors:  D J Touw; A A Vinks; J W Mouton; A M Horrevorts
Journal:  Clin Pharmacokinet       Date:  1998-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.